ResultsIQ

ResultsIQ › Latest results › Gujarat Kidney And Super Speciality Limited

Gujarat Kidney And Super Speciality Limited Q2 FY27 earnings call summary

NSE: GKSL · BSE: 544666

Earnings call of 5 Nov 2026, summarised by AI from the filing.

Q2 FY27 revenue ₹38.1 cr, up 195% year-on-year, with EBITDA margin at 26.8%; management gave no numeric FY27 guidance.

Key takeaways

  1. Q2 revenue Revenue ₹38.1 cr, up 11% quarter-on-quarter and 195% year-on-year; EBITDA ₹10.2 cr at 26.8% margin.
  2. No numeric guidance Management declined to give FY27 revenue or margin figures, saying the average margin holds at year end with quarterly fluctuation.
  3. Receivables Receivables are on the higher side, mostly accumulated, with government payments taking about 6 months.

Original filing on BSE

Gujarat Kidney And Super Speciality Limited Q2 FY27 results

As filed: Revenue ₹38.1 cr, EBITDA ₹10.2 cr, PAT ₹6.6 cr, EBITDA margin 26.8%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹38.1 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹34.3 cr, EBITDA ₹8.4 cr, PAT ₹5.3 cr, EBITDA margin 24.4%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹34.3 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +25.4% in 28 days (Nifty 500: −3.1%).
  • Q4 FY26: Revenue ₹30.6 cr, EBITDA ₹6.3 cr, PAT ₹4.8 cr, EBITDA margin 20.6%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹30.6 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −5.0% in 28 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹23.3 cr, EBITDA ₹6.9 cr, PAT ₹3.7 cr, EBITDA margin 29.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹23.3 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −4.2% in 30 days (Nifty 500: −7.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Gujarat Kidney And Super Speciality Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.